Last reviewed · How we verify
Dapagliflozin/Pioglitazone
This combination drug reduces blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and activating PPAR-γ to improve insulin sensitivity.
This combination drug reduces blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and activating PPAR-γ to improve insulin sensitivity. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Dapagliflozin/Pioglitazone |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | SGLT2 inhibitor / Thiazolidinedione combination |
| Target | SGLT2 / PPAR-γ |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Dapagliflozin is an SGLT2 inhibitor that blocks reabsorption of glucose in the kidney, promoting glucose excretion in urine. Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ), enhancing insulin sensitivity in muscle and adipose tissue. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Fluid retention / edema
- Weight gain
- Hypoglycemia
- Headache
Key clinical trials
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- SGLT2i, Pioglitazone, and Ketone Production in T1D (PHASE3)
- A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes (PHASE4)
- Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration? (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dapagliflozin/Pioglitazone CI brief — competitive landscape report
- Dapagliflozin/Pioglitazone updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI